Key Takeaways Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Investing.com — フランスの製薬大手Sanofi SA (EPA: SASY )は水曜日、米国上場のバイオテク企業Vigil Neuroscience Inc (NASDAQ: VIGL ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. Vigil shares were trading around $8. The stock was up 36% on the ...